Tango Therapeutics beat Q3 earnings and revenue forecasts, but expects losses through 2028.

Tango Therapeutics reported strong Q3 results on November 4, 2025, beating earnings and revenue estimates with $0.13 EPS and $53.81 million in revenue, surpassing forecasts. Despite the positive report, analysts revised FY2025 loss estimates slightly downward to around $0.92 per share, with continued losses projected through 2028. The company, developing cancer drug TNG908, maintains a market cap of $1.08 billion, with institutional ownership at 78.99%. Insider sales totaled $26.35 million in the quarter. Analyst ratings remain mixed, resulting in a "Moderate Buy" consensus and an average price target of $11.00.